Physician treatment preferences for relapsed/refractory multiple myeloma: a discrete choice experiment

Batchelder, Laurie; Philpott, Stephanie; Divino, Victoria; Boytsov, Natalie; Maiese, Eric M.; Hogea, Cosmina; Buckingham, Trudy; Chen, Chi‐Chang; Rodríguez, Ana María

doi:10.2217/fon-2022-0378

Cited by 3 publications

(3 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A previously published DCE that evaluated physician treatment preferences for patients with relapsed/refractory multiple myeloma reported that overall survival was the highest priority when making treatment decisions. 33 However, that DCE included clinical and safety outcomes such as overall survival, overall response rate, progression-free survival, thrombocytopenia, and neutropenia, which may not be equivocal to the preferences included for evaluation in the current study. Similarly, in a DCE evaluating patient frontline treatment preferences for acute lymphoblastic leukemia, overall survival was the highest priority.…”

Section: Discussionmentioning

confidence: 96%

Patient and Physician Preferences for Acute Myeloid Leukemia Maintenance Treatments Following Hematopoietic Stem Cell Transplantation

Saini,

Griffin,

Pandya

et al. 2023

PPA

View full text Add to dashboard Cite

This study assessed and compared preferences for treatment attributes of maintenance therapies post-hematopoietic stem cell transplantation (HSCT) in patients with acute myeloid leukemia (AML) and in physicians who treat these patients. Patients and Methods: Patients with AML post HSCT and physicians from the United States, United Kingdom, Canada, and Australia (physicians only) completed a web-based discrete choice experiment (DCE). The DCE used inputs identified via a targeted literature review and qualitative interviews to ascertain relevant treatment attributes and associated levels. Six treatment attributes were selected (chance of 2-year relapse-free survival, quality of life [QoL], risk of serious infections, risk of nausea, chance of achieving transfusion independence, and duration of hospitalization annually), each with three or four levels. The experimental design included 36 choice tasks that presented a pair of hypothetical treatment profiles with varying attribute levels; participants chose a preferred treatment for each choice task. Choice tasks were divided into three blocks of 12 tasks each in the patient survey and 4 blocks of 9 tasks each in the physician survey; survey participants were randomly assigned to one of the blocks. Random parameter logit regression models were used to assess the impact of stated attributes on preferences for maintenance treatment post HSCT. Results: Surveys from 84 patients and 149 physicians were assessed. For patients, QoL was the most important attribute, followed by duration of hospitalization and chance of 2-year relapse-free survival. For physicians, chance of 2-year relapse-free survival was the most important attribute, followed by QoL and risk of serious infections. Conclusion: Differences in how patients and physicians valued post-HSCT maintenance treatment attributes were identified. These differences suggest that patient-centered decision-making may help physicians choose maintenance treatments for patients with AML post HSCT that better meet their treatment needs and improve their treatment satisfaction.Plain Language Summary: Patients with acute myeloid leukemia (AML) are often treated with chemotherapy followed by stem cell transplantation (SCT). Following SCT, evidence suggests that some patients may benefit from maintenance therapy. In this study, researchers surveyed patients and physicians who treat patients with AML to understand what maintenance treatment characteristics they most valued following SCT. Characteristics evaluated during the survey were chance of survival without relapse, impact on quality of life, risk of serious infections, risk of nausea, chance of being free of needing blood transfusions, and impact on annual hospital length of stay. For patients, the most important maintenance treatment characteristics were better quality of life and fewer hospital days annually. For physicians, the most important maintenance treatment characteristic was a higher chance of survival without relapse. These results show differences in maintenance ...

show abstract

Section: Discussionmentioning

confidence: 96%

Patient and Physician Preferences for Acute Myeloid Leukemia Maintenance Treatments Following Hematopoietic Stem Cell Transplantation

Saini,

Griffin,

Pandya

et al. 2023

PPA

View full text Add to dashboard Cite

show abstract

“…A key driver of discordance between patients and physicians could be differences in priorities for treatment outcomes. Previous studies show that increasing survival is the most important outcome of treatment for both patients and physicians [ 11 ], but patients also place high importance on other factors, such as avoiding treatment side effects [ 12 ]. In the present study, HRQoL appeared worse in patients who reported higher levels of side-effect bother, suggesting that perception of treatment side effects influenced HRQoL.…”

Section: Discussionmentioning

confidence: 99%

“…With each successive LOT, treatment options for patients with MM have become increasingly complex due to the number of available regimens for patients with relapsed/refractory MM (RRMM) [ 4 ]. Studies have shown that in real-world practice, physicians tend to have a greater focus on survival outcomes when making treatment choices, with less consideration of other factors such as side effects and the need for patient visits [ 11 ]. Although patients also prioritize survival, they place higher importance on additional factors known to influence HRQoL, such as minimizing treatment side effects and offsetting financial burdens [ 12 ].…”

Section: Introductionmentioning

confidence: 99%

Real-world patient-reported outcomes and concordance between patient and physician reporting of side effects across lines of therapy in multiple myeloma within the USA

Ribbands

Boytsov

Bailey

et al. 2023

Support Care Cancer

Self Cite

View full text Add to dashboard Cite

Purpose We aimed to explore patient-reported outcomes (PROs) and patient and physician concordance of side effects perception across lines of therapy (LOT) in multiple myeloma (MM) within the United States of America (USA). Methods Data were drawn from the Adelphi Real World MM III Disease Specific Programme™, a point-in-time survey of hemato-oncologists/hematologists and their patients with MM conducted in the USA between August 2020 and July 2021. Physicians reported patient characteristics and side effects. Patients reported side-effect bother and health-related quality of life (HRQoL) using validated PRO tools (European Organisation for the Research and Treatment of Cancer Quality of Life Core Questionnaire/-MM Module [EORTC QLQ-C30/-MY20], EQ-5D-3L and Functional Assessment of Cancer Therapy—General Population physical item 5). Descriptive, linear regression and concordance analyses were performed. Results Records from 63 physicians and 132 patients with MM were analyzed. EORTC QLQ-C30/-MY20 and EQ-5D-3L scores were consistent across LOTs. Scores tended to be worse with higher side-effect bother; patients “very much” bothered by side effects had lower median (interquartile range) global health status scores (33.3 [25.0–50.0]) than those “not at all” bothered (79.2 [66.7–83.3]). Patient and physician concordance on side-effect reporting was poor to fair. Patients frequently reported fatigue and nausea as bothersome side effects. Conclusion HRQoL of patients with MM was worse with greater side-effect bother. Discordant patient and physician reporting of side effects indicated a need for improved communication during management of MM.

show abstract

Drivers of physician decision-making and patient perspectives across lines of therapy in multiple myeloma in the USA

et al. 2023

View full text Add to dashboard Cite

Aim: To explore treatment selection for relapsed/refractory multiple myeloma (RRMM), which remains complex due to heterogeneity of available treatments and lack of defined standard of care. Patients & methods: The Adelphi Real World MM Disease Specific Programme surveyed physicians in the USA and their patients with MM to collect real-world data on patterns and perceptions of MM treatment across lines of therapy (LOT). Results: Triplets were the most common regimens across each LOT. Physicians reported efficacy-related factors, health insurance coverage, and clinical guidelines as key determinants of treatment choice regardless of LOT. Patients identified better quality of life as the most important treatment benefit. Conclusion: The DSP RW data highlight drivers of RRMM treatment choice from physicians' and patients' perspectives and need for a more holistic approach to guidelines and clinical trials that encompasses patient perspectives.

show abstract

Physician treatment preferences for relapsed/refractory multiple myeloma: a discrete choice experiment

Cited by 3 publications

References 49 publications

Patient and Physician Preferences for Acute Myeloid Leukemia Maintenance Treatments Following Hematopoietic Stem Cell Transplantation

Patient and Physician Preferences for Acute Myeloid Leukemia Maintenance Treatments Following Hematopoietic Stem Cell Transplantation

Real-world patient-reported outcomes and concordance between patient and physician reporting of side effects across lines of therapy in multiple myeloma within the USA

Drivers of physician decision-making and patient perspectives across lines of therapy in multiple myeloma in the USA

Contact Info

Product

Resources

About